|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C12orf44 |
Gene summary for C12ORF44 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C12orf44 | Gene ID | 60673 |
| Gene name | autophagy related 101 | |
| Gene Alias | C12orf44 | |
| Cytomap | 12q13.13 | |
| Gene Type | protein-coding | GO ID | GO:0000045 | UniProtAcc | A0A024R128 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 60673 | C12orf44 | P1_S1_AK | Human | Skin | AK | 1.65e-13 | -3.33e-01 | -0.3399 |
| 60673 | C12orf44 | P2_S3_AK | Human | Skin | AK | 1.65e-13 | -3.33e-01 | -0.3287 |
| 60673 | C12orf44 | P2_S4_SCCIS | Human | Skin | SCCIS | 3.67e-13 | -3.33e-01 | -0.3043 |
| 60673 | C12orf44 | P3_S6_AK | Human | Skin | AK | 7.41e-14 | -3.33e-01 | -0.3256 |
| 60673 | C12orf44 | P4_S8_cSCC | Human | Skin | cSCC | 4.57e-07 | -3.33e-01 | -0.3095 |
| 60673 | C12orf44 | P5_S10_cSCC | Human | Skin | cSCC | 7.41e-14 | -3.33e-01 | -0.299 |
| 60673 | C12orf44 | P1_cSCC | Human | Skin | cSCC | 2.02e-10 | 6.08e-01 | 0.0292 |
| 60673 | C12orf44 | P2_cSCC | Human | Skin | cSCC | 2.75e-06 | 4.34e-01 | -0.024 |
| 60673 | C12orf44 | P4_cSCC | Human | Skin | cSCC | 8.36e-17 | 5.31e-01 | -0.00290000000000005 |
| 60673 | C12orf44 | P10_cSCC | Human | Skin | cSCC | 7.10e-12 | 6.10e-01 | 0.1017 |
| 60673 | C12orf44 | cSCC_p1 | Human | Skin | cSCC | 1.65e-13 | -3.33e-01 | -0.1916 |
| 60673 | C12orf44 | cSCC_p10 | Human | Skin | cSCC | 1.65e-13 | -3.33e-01 | -0.2095 |
| 60673 | C12orf44 | cSCC_p11 | Human | Skin | cSCC | 7.41e-14 | -3.33e-01 | -0.2102 |
| 60673 | C12orf44 | cSCC_p3 | Human | Skin | cSCC | 1.65e-13 | -3.33e-01 | -0.2085 |
| 60673 | C12orf44 | cSCC_p4 | Human | Skin | cSCC | 1.93e-11 | -3.33e-01 | -0.2022 |
| 60673 | C12orf44 | cSCC_p6 | Human | Skin | cSCC | 1.65e-13 | -3.33e-01 | -0.1989 |
| 60673 | C12orf44 | cSCC_p7 | Human | Skin | cSCC | 1.93e-11 | -3.33e-01 | -0.2332 |
| 60673 | C12orf44 | cSCC_p8 | Human | Skin | cSCC | 1.65e-13 | -3.33e-01 | -0.1971 |
| 60673 | C12orf44 | cSCC_p9 | Human | Skin | cSCC | 7.41e-14 | -3.33e-01 | -0.1991 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa05016210 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
| hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
| hsa0414010 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
| hsa0501728 | Esophagus | ESCC | Spinocerebellar ataxia | 94/4205 | 143/8465 | 6.77e-05 | 2.90e-04 | 1.48e-04 | 94 |
| hsa0421114 | Esophagus | ESCC | Longevity regulating pathway | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
| hsa041362 | Esophagus | ESCC | Autophagy - other | 23/4205 | 32/8465 | 8.99e-03 | 2.14e-02 | 1.09e-02 | 23 |
| hsa0501438 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa0501638 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
| hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa0501038 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
| hsa0414015 | Esophagus | ESCC | Autophagy - animal | 101/4205 | 141/8465 | 7.60e-08 | 6.21e-07 | 3.18e-07 | 101 |
| hsa0501736 | Esophagus | ESCC | Spinocerebellar ataxia | 94/4205 | 143/8465 | 6.77e-05 | 2.90e-04 | 1.48e-04 | 94 |
| hsa0421115 | Esophagus | ESCC | Longevity regulating pathway | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
| hsa0413611 | Esophagus | ESCC | Autophagy - other | 23/4205 | 32/8465 | 8.99e-03 | 2.14e-02 | 1.09e-02 | 23 |
| hsa0501614 | Liver | Cirrhotic | Huntington disease | 172/2530 | 306/8465 | 1.65e-22 | 1.10e-20 | 6.77e-21 | 172 |
| hsa0501414 | Liver | Cirrhotic | Amyotrophic lateral sclerosis | 187/2530 | 364/8465 | 1.56e-18 | 6.50e-17 | 4.01e-17 | 187 |
| hsa0502214 | Liver | Cirrhotic | Pathways of neurodegeneration - multiple diseases | 217/2530 | 476/8465 | 7.30e-14 | 2.03e-12 | 1.25e-12 | 217 |
| hsa0501014 | Liver | Cirrhotic | Alzheimer disease | 180/2530 | 384/8465 | 5.52e-13 | 1.36e-11 | 8.36e-12 | 180 |
| Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |